Drug Type Small molecule drug |
Synonyms NA 931, NA931 |
Mechanism GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity | Phase 3 | US | - | |
Diabetes Mellitus, Type 2 | Phase 1 | AU | 06 May 2024 |
Phase 1 | - | zkxnrknsrk(nqiizstkmg) = wxiasakyru kbrjihpzvl (bzpkinoxqa ) View more | Positive | 07 Oct 2024 | |||
Placebo | zkxnrknsrk(nqiizstkmg) = skkqguqkgq kbrjihpzvl (bzpkinoxqa ) | ||||||
Not Applicable | glucose | lipids | - | waotbbjrdk(nrbnwnhfyd) = sydrezauzm pfviwnblhn (uqoqogqmpk ) | Positive | 14 Jun 2024 | ||
NA-932 | waotbbjrdk(nrbnwnhfyd) = lftsioprvw pfviwnblhn (uqoqogqmpk ) |